Department of Neurosurgery, West China Hospital, Sichuan University, China.
Clin Neurol Neurosurg. 2021 Jan;200:106385. doi: 10.1016/j.clineuro.2020.106385. Epub 2020 Nov 28.
To compare the efficacy and safety between primary GKS and postoperative GKS for acromegaly, and to elucidate predictors associated with endocrine remission, we performed a monocenter, retrospective study.
Seventy-five patients with acromegaly who had received GKS in West China Hospital between March 2010 and December 2018 were included in this study. Endocrine remission was defined as age-sex matched IGF-I normalization and either nadir level of GH <1 ng/mL after OGTT or the random GH < 2.0 ng/mL.
We didn't find significant differences in endocrine remission, biochemical recurrence, imaging regression, imaging progression, radiation-induced complications between the primary GKS group and the postoperative GKS group(P > 0.05). Actuarial rates of durable endocrine remission at 3, 5, 8 year were 10.60 %, 33.80 % and 70.60 % in the primary GKS group and 6.70 %, 43.40 % and 78.80 % in the postoperative GKS group(P = 0.800). Only base nadir GH after OGTT (HR = 0.637,95 % CI:0.416-0.977; P = 0.039) was found to be a predictor of duration endocrine remission.
We find comparable efficacy and safety between primary GKS and postoperative GKS. Lower base nadir GH after OGTT was a positive predictor associated with endocrine remission. GKS should be considered for residual or recurrent tumor after surgery. For those who couldn't sustain surgery, GKS is an alternative treatment. Further studies are required to elucidate the efficacy and safety of GKS in acromegaly.
比较初诊与术后行伽玛刀治疗肢端肥大症的疗效和安全性,并阐明与内分泌缓解相关的预测因素,我们进行了一项单中心回顾性研究。
本研究纳入了 2010 年 3 月至 2018 年 12 月期间在华西医院接受伽玛刀治疗的 75 例肢端肥大症患者。内分泌缓解定义为 IGF-I 与年龄和性别匹配正常,且 OGTT 后 GH 谷值<1ng/ml 或随机 GH<2.0ng/ml。
我们未发现初诊组与术后组在内分泌缓解、生化复发、影像学缓解、影像学进展、放射性并发症方面存在显著差异(P>0.05)。初诊组和术后组的持久内分泌缓解累积率在 3、5、8 年时分别为 10.60%、33.80%和 70.60%和 6.70%、43.40%和 78.80%(P=0.800)。仅 OGTT 后基础 GH 谷值(HR=0.637,95%CI:0.416-0.977;P=0.039)被发现是内分泌缓解持续时间的预测因素。
我们发现初诊与术后行伽玛刀治疗肢端肥大症的疗效和安全性相当。OGTT 后基础 GH 谷值较低是与内分泌缓解相关的积极预测因素。对于术后残留或复发的肿瘤,应考虑伽玛刀治疗。对于那些不能持续手术的患者,伽玛刀是一种替代治疗。需要进一步研究来阐明伽玛刀治疗肢端肥大症的疗效和安全性。